编辑: ok2015 | 2019-07-16 |
4 In August 2001, Yichang Changjiang Pharmaceutical Co., Ltd., the predecessor of the Company, was established in Hubei Province and formally entered into China pharmaceutical industry. In 2006, the Company was licensed by oseltamiv phosphate licensor to manufacture oseltamivir phosphate products in the PRC. In 2008, following the registration of its exclusive patent-protected Kewei granule product with the China Food and Drug Administration of (the CFDA ), the Company became the only oseltamivir phosphate granule manufacturer in China and entered the domestic pediatric pharmaceutical market. In the following year, the Company'
s anti-influenza virus product, oseltamivir phosphate, was selected into Central Medical Reserve (中央医药储备基 地). In 2013, Kewei product dominated the largest market share of oseltamivir phosphate products in China. In 2015, the Company was transformed into a joint stock limited company by means of reorganization, and established strategic cooperation relationship with Shenzhen HEC Industrial, our controlling shareholder, and acquired the pre-emptive right to purchase products developed by the HEC Research Group (东阳光药研究院)1 owned by our controlling shareholder. With the continuous expansion of our business, shares of the Company were successfully listed on The Stock Exchange of Hong Kong Limited (the Stock Exchange ) on
29 December 2015. Since its establishment, the Company has been adhering to the development strategies of professionalism, branding and differentiation. Since 2014, the Company has been committed to building a professional marketing team, maintaining steady and innovative market operation and implementing strategic integration of resources, so as to develop unique brand characteristics and core competitiveness HEC Pharm in the industry and create maximized value for our consumers and partners. In future, the Company will further enrich its product lines, expand its markets, enhance international production standards and quality of its products and continue to expand the coverage of marketing and sales in order to promote further growth of our operations and profitability, and endeavour to create more value for the investors.
1 HEC Research Group (东阳光药研究院) has three major specific institutes, being innovative drugs, biologics and generic drugs institutes. After over
10 years of development, with the establishment of a research and development (R&
D) system which can meet the research standards of the FDA and in Europe in relation to new drugs, the institute has become a R&
D base for new drugs, biologics and generic drugs with international first-class R&
D strength. 2001年8月,本公司前身 「宜昌长江药业有限公 司」 在湖北省成立,并正式进入中国医药行业. 於2006年,本公司获得磷酸奥司他韦许可方许 可在中国生产磷酸奥司他韦产品.於2008年, 可威颗粒剂独家专利产品於中国国家食品药品 监督管理总局 ( 「国家药监总局」 ) 登记注册, 本公司成为中国唯一一家磷酸奥司他韦颗粒剂 生产商,进军儿科医药市场.次年,抗流感病 毒药物磷酸奥司他韦产品列入中央医药储备基 地.於2013年,可威产品占泄姿岚滤舅 韦产品市场最大份额.於2015年,本公司重 组改制成为股份有限公司,并与控股股东深东 实建立战略合作关系,获其下属东阳光药研究院1 研发成果的优先购买权.随著本集团业务不断 扩展,本公司股份於2015年12月29日在香港 联合交易所有限公司 ( 「联交所」 ) 正式挂牌交 易. 自成立以来,本公司始终坚持实施专业化、品 牌化、差异化的发展战略,2014年起本公司致 力於自营销售团的专业性打造、稳健创新的 市场运作、战略性的资源整合,在行业内创造 东阳光药独有的品牌特色和核心竞争力,为消 费者、合作夥伴创造最大的价值.在未来,本 公司将进一步丰富产品线,开拓市场,提升产 品的国际化生产标准及产品质量,继续扩大市 场推广及销售围,以促进我们业务及盈利能 力的进一步增长,为广大投资者创造更大的价 值.